ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
19 Jul 2020 14:14

ECM Weekly (19 July 2020) - HK IPO Analytics 1H2020, Shimao Services, AyalaLand REIT, Li Auto

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Hong...

Share
bullishLonza Group AG
17 Jul 2020 10:48

Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex

Over the next few weeks/months, we will be initiating coverage on a few key players in the Global CDMO space, where we see interesting growth...

Logo
443 Views
Share
bullishWuxi Biologics
16 Jul 2020 10:21

Wuxi Biologics - Recap/Learnings from past Placements

Wuxi Biologics (Cayman) Inc (2269 HK) has seen a total of ten placements since listing in Jun 2017. We've covered all of the deals. Given that the...

Logo
469 Views
Share
12 Jul 2020 11:47

Hong Kong Connect Weekly:  $1bn Inflows into Tencent and Xiaomi

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong...

Logo
281 Views
Share
11 Jul 2020 14:37

Asia Short Interest Weekly - PingAn, WuXi Bio, Meituan, SMIC, Fast Retail, Sumitomo, Yageo, Genius

The Asia Short Interest weekly looks at moves in market wide short interest and highlights movements in stock specific short interest across Hong...

Logo
305 Views
Share
x